Sofosbuvir is a nucleotide analog polymerase inhibitor, the first FDA-approved all-oral treatment for patients with HCV genotypes 2 or 3.
The drug received approval shortly after simpeprevir, an Olysio, Janssen Therapeutics drug for patients with HCV genotype 1.
Sofosbuvir is a product of Gilead Sciences.
More Articles on Gastroenterology:
5 Current Treatments for Ulcerative Colitis
New Test Offers Promise of Simpler Celiac Disease Diagnosis
5 Things to Know About Advances in Oral Treatment for Hepatitis C
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 18–20 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
